Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis:.a multicenter, retrospective study / Nettis, E; Ferrucci, S M; Ortoncelli, M; Pellacani, G; Foti, C; Di Leo, E; Patruno, C; Rongioletti, F; Argenziano, G; Macchia, L; Tavecchio, S; Napolitano, M; Ribero, S; Bonzano, L; Romita, P; Di Bona, D; Nisticò, S P; Piras, V; Calabrese, G; Detoraki, C; Carbonara, M; Fabbrocini, G. - In: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY. - ISSN 1018-9068. - 32:2(2022), pp. 124-132. [10.18176/jiaci.0641]
Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis:.a multicenter, retrospective study
Pellacani, G;Nisticò, S P;
2022
Abstract
Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.| File | Dimensione | Formato | |
|---|---|---|---|
|
Nettis_Use-Of-Dupilumab_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
380.64 kB
Formato
Adobe PDF
|
380.64 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
